Seminars in Hematology
Volume 43 , Pages S4-S9 , April 2006

Infectious Disease in the Blood Supply and the Public Health Response

  • Bruce Evatt

      Affiliations

    • Corresponding Author InformationAddress correspondence to Bruce Evatt, MD, Chief (Retired), Hematologic Diseases Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 2094 Valiant Dr NE, Atlanta, GA 30345.

References 

  1. Jones PK , Ratnoff OD . The changing prognosis of classic hemophilia (factor VIII “deficiency”) . Ann Intern Med . 1991;114:641–648
  2. Public Health Service Act . 1975; Section 606 of P.L. 94-63 amended Title XI of the Public Health Service Act
  3. Soucie JM , Nuss R , Evatt B , Abdelhak A , Cowan L , Hill H , et al.   Mortality among males with hemophilia with source of medical care . Blood . 2000;96:437–442
  4. Troisi CL , Hollinger FB , Hoots WK , Contant C , Gill J , Ragni M , et al.   A multicenter study of viral hepatitis in the United States hemophilic population . Blood . 1993;81:412–418
  5. American Association of Blood Banks: Frequently Asked Questions. Available at: http://www.aabb.org/All_About_Blood/FAQs/aabb_faqs.htm, accessed December 2005
  6. In:  Leveton LB ,  Sox HC ,  Stoto MA editor. HIV and the Blood Supply (An Analysis of Crisis Decisionmaking) . Washington, DC: National Academy Press; 1995;
  7. Centers for Disease Control and Prevention . Epidemiologic notes and reports Pneumocystis carinii pneumonia among persons with hemophilia A . MMWR Morb Mortal Wkly Rep . 1982;31:365–367
  8. Centers for Disease Control and Prevention . Human immunodeficiency virus infection in the United States (A review of current knowledge) . MMWR Morb Mortal Wkly Rep . 1987;36:1–20
  9. Chorba TL , Holman RC , Clarke MJ , Evatt BL . Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States . Am J Hematol . 2001;66:229–240
  10. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research . Workshop on factor VIII inhibitors . 2003; Proceedings of the Food and Drug Administration International Association of Biologicals Workshop on Factor VIII Inhibitors; November 21; Bethesda, MD. Available at www.fda.gov/cber/minutes/fctrviii112103t.pdf, accessed December 2005
  11. Josić D , Buchacher A , Kannicht C , Lim YP , Loster K , Pock K , et al.   Degradation products of factor VIII which can lead to increased immunogenicity . Vox Sang . 1999;77(suppl 1):90–99
  12. McDougal JS , Martin LS , Cort SP , Mozen M , Heldebrant CM , Evatt BL . Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor . J Clin Invest . 1985;76:875–877
  13. Food and Drug Administration . FDA Approves First Nucleic Acid Test (NAT) Systems to Screen Plasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) . Rockville, MD: National Press Office; 2001; September 21. Talk Paper T01-42
  14. Soucie JM , Richardson LC , Evatt BL , Linden JV , Ewenstein BM , Stein SF , et al.   Risk factors for infection with HBV and HCV in a large cohort of hemophiliac males . Transfusion . 2001;41:338–343
  15. American Red Cross: How blood is tested. Available at http://www.pleasegiveblood.org/education/blood_tested.php, accessed December 2005
  16. Busch MP , Kleinman SH , Nemo GJ . Current and emerging infectious risks of blood transfusions . JAMA . 2003;289:959–962
  17. Schreiber GB , Busch MP , Kleinman SH , Korelitz JJ  Retrovirus Epidemiology Donor Study . The risk of transfusion-transmitted viral infections . N Engl J Med . 1996;336:1685–1690
  18. Teitel JM . Viral safety of haemophilia treatment products . Ann Med . 2000;32:485–492
  19. Burnouf T , Radosevich M . Nanofiltration of plasma-derived biopharmaceutical products . Haemophilia . 2003;9:24–37
  20. Ananyeva N , Khrenov A , Darr F , Summers R , Sarafanov A , Saenko E . Treating haemophilia A with recombinant blood factors (A comparison) . Expert Opin Pharmacother . 2004;5:1061–1070
  21. Schlesinger KW , Ragni MV . Safety of the new generation recombinant factor concentrates . Expert Opin Drug Saf . 2002;1:213–223
  22. Van der Poel CL , Siefried E , Schaasberg WP . Paying for blood donations (Still a risk?) . Vox Sang . 2002;83: 385–293
  23. Evatt BL , Austin H , Leon G , Ruiz-Saez A , De Bosch N . Predicting the long-term risk of HIV exposure by cryoprecipitate . Haemophilia . 2000;6(suppl 1):128–132
  24. Dodd RY . Emerging infections, transfusion safety, and epidemiology . N Engl J Med . 2003;349:1205–1206
  25. Llewelyn CA , Hewitt PE , Knight RS , Amar K , Cousens S , Mackenzie J , et al.   Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion . Lancet . 2004;363:417–421
  26. Peden AH , Head MW , Ritchie DL , Bell JE , Ironside JW . Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient . Lancet . 2004;364:527–529
  27. Department of Health . Assessing the risk of vCJD transmission via surgery (An interim review) . 2005; March. Available at: http://www.dh.gov.uk/assetRoot/04/11/35/42/04113542.pdf, accessed December 2005
  28. Department of Health . Guidance on local reporting by clinicians of Creutzfeldt-Jakob Disease (CJD) and local action by consultants in communicable disease control (CsCDC) . 2003; November. Available at: http://www.cjd.ed.ac.uk/guidance.htm, accessed December 2005
  29. Department of Health . Assessing the implications for blood donors if recipients are infected with vCJD . 2005; July. Available at: http://www.dh.gov.uk/assetRoot/04/11/53/12/04115312.pdf, accessed December 2005

PII: S0037-1963(06)00025-4

doi: 10.1053/j.seminhematol.2006.02.001

Seminars in Hematology
Volume 43 , Pages S4-S9 , April 2006

Article Tools

* Image Usage & Resolution